Phantom Neuro, a neurotechnology company developing a minimally invasive interface that enables intuitive control of prosthetic limbs and robotic exoskeletons, announced an oversubscribed $19 million Series A funding round that was led by Ottobock. The round included participation from new and existing investors. As part of the investment, Ottobock will join Phantom Neuro’s board of directors.
The investment brings Phantom Neuro’s total funding to $28 million to support preclinical testing, completion of first-in-human trials, regulatory submissions, and expanded research and development for broader control applications beyond prosthetic limbs.
“Ottobock’s backing underscores the growing convergence of neurotechnology, prosthetics, and robotics,” said Connor Glass, MD, Phantom Neuro founder and CEO. “For decades, Ottobock has been at the forefront of restoring mobility for millions of people. By partnering with them, we’re accelerating Phantom X’s path to market and laying the groundwork for the future we all desire where assistive devices truly function as natural extensions of the human body.”
“Phantom Neuro is transforming the way people interact with assistive devices, and their minimally invasive neural interface technology represents an exciting step forward for the field,” said Ottobock CEO Oliver Jakobi.
The funding follows Phantom Neuro’s Breakthrough Device Designation and Targeted Acceleration Pathway designation from the US Food and Drug Administration for Phantom X in March.
